Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine

Background: Treatment-resistant depression (TRD) and pain frequently coexist clinically. Ketamine has analgesic and antidepressant effects, but few studies have evaluated individual differences in antidepressant outcomes to repeated ketamine in TRD patients with comorbid pain. Our aims were to determine the difference in ketamine's antidepressant effects in TRD patients with or without pain and then to examine whether inflammatory cytokines might contribute to ketamine's effect. Methods: Sixty-six patients with TRD received six infusions of ketamine. Plasma levels of 19 inflammatory cytokines were assessed at baseline and post-infusion (day 13 and day 26) using the Luminex assay. Plasma inflammatory cytokines of sixty healthy controls (HCs) were also examined. Results: TRD patients with pain had a higher antidepressant response rate (chi(2) = 4.062, P = 0.044) and remission rate (chi(2) = 4.062, P = 0.044) than patients without pain. Before ketamine treatment, GM-CSF and IL-6 levels were higher in the pain group than in the non-pain and HC groups. In the pain group, levels of TNF-alpha and IL-6 at day 13 and GM-CSF, fractalkine, IFN-gamma, IL-10, MIP-3 alpha, IL-12P70, IL-17 alpha, IL-1 beta, IL-2, IL-4, IL-23, IL-5, IL-6, IL-7, MIP-1 beta, and TNF-alpha at day 26 were lower than those at baseline; in the non-pain group, TNF-alpha levels at day 13 and day 26 were lower than those at baseline. In the pain group, the changes of IL-6 were associated with improvement in pain intensity (beta = 0.333, P = 0.001) and depressive symptoms (beta = 0.478, P = 0.005) at day 13. Path analysis showed the direct (beta = 2.995, P = 0.028) and indirect (beta = 0.867, P = 0.042) effects of changes of IL-6 on improvement in depressive symptoms both were statistically significant. Conclusion: This study suggested that an elevated inflammatory response plays a critical role in individual differences in TRD patients with or without pain. Ketamine showed great antidepressant and analgesic effects in TRD patients with pain, which may be related to its effects on modulating inflammation.

Automated summary

The study showed that TRD patients with pain had a higher antidepressant response rate and remission rate compared to those without pain. Before treatment, inflammatory cytokine levels were higher in the pain group. Additionally, changes in inflammatory cytokines, particularly IL-6, were associated with improvements in pain intensity and depressive symptoms in the pain group.